<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798239</url>
  </required_header>
  <id_info>
    <org_study_id>PFX-101</org_study_id>
    <nct_id>NCT00798239</nct_id>
  </id_info>
  <brief_title>Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery</brief_title>
  <official_title>A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioSurface Engineering Technologies, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioSurface Engineering Technologies, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaulate the safety and prelimary effectiveness of Prefix as
      compared to autogenous bone for spinal fusion procedures in skeletally mature subjects with
      degenerative disc disease (DDD) at one level from L2-S1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not available
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Removal/revision or supplemental fixation of the graft material requiring reoperation at the index level, Safety (adverse events), Fusion &quot;success&quot; based on X-rays, Change from baseline in neurological exam scores and ODI scores</measure>
    <time_frame>12 months post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of blood loss/transfused blood during surgery, Blinded independent assessment of fusion by CT and other radiographic assessments, Change from baseline in pain scores using VAS and change from baseline in SF-36 v2â„¢ total and subscale scores</measure>
    <time_frame>12 months post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spondylolisthesis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control arm is Iliac Crest Autograft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prefix 150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prefix 750</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prefix (AMPLEX) B2A Enhanced Ceramic Granules</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules</intervention_name>
    <description>150 micorgrams/cc BVF</description>
    <arm_group_label>Prefix 150</arm_group_label>
    <other_name>AMPLEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iliac crest autograft</intervention_name>
    <description>autograft</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules</intervention_name>
    <description>750 micrograms/cc BVF</description>
    <arm_group_label>Prefix 750</arm_group_label>
    <other_name>AMPLEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of DDD requiring single level fusion (L2-S1) with up to Grade I
             Spondylolisthesis

          -  Have a preoperative screening qualifying VAS and ODI scores

          -  Be a skeletally mature male or a non-pregnant, non-lactating female, age 18 -70
             inclusive

          -  Have not been sufficiently responsive to at least 6 months of non-operative treatment
             prior to study enrollment

        Exclusion Criteria:

          -  Are female subjects who are pregnant or nursing, or women planning to become pregnant
             during the first year (12 months) following the surgery

          -  A history of previous surgery in the lumbar spine with or without attempted fusion

          -  Grade II or greater spondylolisthesis

          -  More than 0 degrees of kyphosis at the operated disc space

          -  Evidence of scoliosis in the lumbar region of more than 10 degrees

          -  Collapsed disc space with bridging osteophytes

          -  A systemic or local infection at the site of surgery

          -  An acute fracture of the spine at the time of enrollment in the study

          -  An active history of systemic malignancy

          -  A medical condition, serious intercurrent illness, or extenuating circumstance that,
             in the opinion of the Investigator, would preclude participation in the study

          -  A known hypersensitivity to any of the components of the product or a known titanium
             allergy or a known allergy to polyetheretherketone (PEEK)

          -  A history of any autoimmune disease, such as, systemic lupus erythematosus, Addison's
             disease, Crohn's disease, or rheumatoid arthritis

          -  A history of any severe allergy or anaphylaxis, or a history of hypersensitivity to
             protein pharmaceuticals, or have had any previous exposure to a protein pharmaceutical

          -  Are receiving treatment (before or during surgery) with a drug (e.g., steroids,
             methotrexate, etc.) that interferes with bone metabolism or are being treated with a
             bone growth stimulator

          -  A medical condition requiring radiation, chemotherapy or immunosuppression, or a
             medical condition requiring systemic corticosteroids

          -  Are covered under workmen's compensation insurance or prisoners

          -  Are transient or have been treated in the last 6 months before enrollment for alcohol
             and/or drug abuse in an in-subject substance abuse program

          -  Have participated in clinical studies within 3 months of enrollment

          -  Have a body mass index (BMI) greater than 35

          -  Use tobacco products (also includes, e.g. nicotine patch or nicotine gum), or have
             smoked cigarettes within 6 weeks preceding enrollment

          -  Known to require additional surgery to the lumbar spinal region within the next 6
             months

          -  Have symptomatic multilevel degenerative disease requiring possible instrumented
             fusion of more than one vertebral level

          -  Have previously been treated with, or exposed to, therapeutic levels of Bone
             Morphogenetic Proteins (BMPs), i.e., synthetic or recombinant

          -  Have a documented medical history or radiographic evidence of a metabolic bone disease
             (e.g., osteoporosis or osteopenia) or other condition which would negatively impact
             the bone healing process (e.g. history of Paget's disease, osteomalacia, or other
             osteodystrophy) or preclude the subject from receiving pedicle screw fixation

          -  Are involved in or planning to engage in litigation related to back and/or leg pain

          -  Require chronic SQ or IV heparin therapies

          -  Have an Osteoporosis Risk Assessment Instrument (ORAI) score &gt; to 9 points and, if so,
             will require a qualifying DEXA scan T score
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent Atkinson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioSurface Engineering Technologies, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Confidential</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confidential</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confidential</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confidential</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confidential</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DDD</keyword>
  <keyword>Spondylolisthesis</keyword>
  <keyword>Spine Fusion</keyword>
  <keyword>Lumbar Spine</keyword>
  <keyword>Bone Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

